Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Simulations Plus to Present at 15th Annual Needham Virtual Technology & Media Conference

BusinessWire_EN 
0 0 13.05.20
Simulations Plus to Present at 15th Annual Needham Virtual Technology & Media Conference
 

Simulations Plus, Inc. (Nasdaq: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will present at the 15th Annual Needham Virtual Technology & Media Conference on Wednesday, May 20, at 10:00 a.m. ET. In addition to his presentation, Mr. O’Connor will host one-on-one meetings throughout the day.

This year’s conference will provide shareholders and investors the opportunity to see presentations from more than 150 leading public and private companies in the Technology and Media sectors in a structured and user-friendly virtual setting. For more information about the conference or to schedule a one-on-one meeting with Mr. O’Connor, please contact Hayden IR at [email protected].

About Simulations Plus, Inc.

Simulations Plus, Inc. is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions and quantitative systems pharmacology models for drug-induced liver injury, drug-induced kidney injury, and nonalcoholic fatty liver disease. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical, biotechnology, and chemical agents. Our software is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, chemical, and consumer goods companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation. For more information, visit our website at www.simulations-plus.com.

Follow us on Twitter | LinkedIn | YouTube

View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005106/en/

Simulations Plus Stock

€34.00
4.290%
A very strong showing by Simulations Plus today, with an increase of €1.40 (4.290%) compared to yesterday's price.
The community is currently still undecided about Simulations Plus with 1 Buy predictions and 0 Sell predictions.
With a target price of 46 € there is a positive potential of 35.29% for Simulations Plus compared to the current price of 34.0 €.
Show more
Like: 0
Share
BusinessWire_EN 
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Legal notice

Comments

Not a member yet? Sign up for free!